James E. Fickenscher - Jul 18, 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
Chief Financial Officer
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Stock symbol
ZYNE
Transactions as of
Jul 18, 2022
Transactions value $
-$6,614
Form type
4
Date filed
7/20/2022, 04:05 PM
Previous filing
Jan 28, 2022
Next filing
Jan 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award +20.8K +13.19% 179K Jul 18, 2022 Direct F1
transaction ZYNE Common Stock Sale -$6.61K -6.01K -3.37% $1.10 173K Jul 19, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 20,800 performance-based restricted stock awards granted in a prior year.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.